monsitj Wells Fargo initiated coverage of Verona Pharma ( NASDAQ: VRNA ) with an overweight rating, asserting that the company's recently launched drug for COPD, Ohtuvayre, is being undervalued by the Street. The investment bank said the market has been pricing in peak sales.
Back to Health Page
